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The WISDOM Study: breaking the deadlock in the breast
cancer screening debate
Laura J. Esserman1 and the WISDOM Study and Athena Investigators31
There are few medical issues that have generated as much controversy as screening for breast cancer. In science, controversy often
stimulates innovation; however, the intensely divisive debate over mammographic screening has had the opposite effect and has
stifled progress. The same two questions—whether it is better to screen annually or bi-annually, and whether women are best
served by beginning screening at 40 or some later age—have been debated for 20 years, based on data generated three to four
decades ago. The controversy has continued largely because our current approach to screening assumes all women have the same
risk for the same type of breast cancer. In fact, we now know that cancers vary tremendously in terms of timing of onset, rate of
growth, and probability of metastasis. In an era of personalized medicine, we have the opportunity to investigate tailored screening
based on a woman’s specific risk for a specific tumor type, generating new data that can inform best practices rather than to
continue the rancorous debate. It is time to move from debate to wisdom by asking new questions and generating new knowledge.
The WISDOM Study (Women Informed to Screen Depending On Measures of risk) is a pragmatic, adaptive, randomized clinical trial
comparing a comprehensive risk-based, or personalized approach to traditional annual breast cancer screening. The multicenter
trial will enroll 100,000 women, powered for a primary endpoint of non-inferiority with respect to the number of late stage cancers
detected. The trial will determine whether screening based on personalized risk is as safe, less morbid, preferred by women, will
facilitate prevention for those most likely to benefit, and adapt as we learn who is at risk for what kind of cancer. Funded by the
Patient Centered Outcomes Research Institute, WISDOM is the product of a multi-year stakeholder engagement process that has
brought together consumers, advocates, primary care physicians, specialists, policy makers, technology companies and payers to
help break the deadlock in this debate and advance towards a new, dynamic approach to breast cancer screening.
npj Breast Cancer  (2017) 3:34 ; doi:10.1038/s41523-017-0035-5
INTRODUCTION
Annual screening mammography—the most common approach
in the US today—has its roots in the large, randomized screening
trials of the 1980s.1 The first trial of annual screening, the U.S.
Health Insurance Plan of Greater New York, began in 1963 and
included 31,000 women in each arm.2 At 18 years of follow-up, it
showed a 25% reduction in mortality, although benefit to women
in their forties accrued after they were 50. The overview of the
Swedish trials of bi- or triennial screening showed a relative
reduction in breast cancer mortality of 21%, with maximum
benefit for women in their sixties.3 The degree and timing of
benefit to younger women in particular has generated a great deal
of controversy.4 Even a decade later, there remains a continuing
debate over the methodologic flaws of each of these studies, the
net effect of which has impeded consensus on public recom-
mendations for breast screening.5–7
From the outset, translating these studies into population-
based screening recommendations stirred controversy, with
debate focused on the frequency and most appropriate age to
begin screening. The January 1997 Consensus Development Panel
convened by the National Institutes of Health recommended
women aged 40–49 be informed of the benefits and risks of
screening and decide for themselves.8 The National Cancer
Institute (NCI) and American Cancer Society (ACS), however,
recommended regular screening for women in their forties while
disagreeing on screening frequency, with the former recommend-
ing every 1–2 years, the latter annually. Partly because of the
controversy generated, the NCI later stopped issuing screening
guidelines.
Now, 20 years later, we find ourselves in a familiar place—still
reviewing and reanalyzing data from the same trials, debating the
optimum age to begin and interval, with professional societies
that set guidelines compelled to “take a side” in the debate. The
controversy following the 2009 JAMA commentary “Rethinking
Screening”9 and updates to USPSTF guidelines10 illustrates how
entrenched both sides have become. Consensus on recommenda-
tions remains distant.
The US Preventative Task Force systematic review concluded in
2015,11 much like it had in 2009,10 that mammographic screening
benefits women over 50 and that biennial, not annual, screening
was recommended for women ages 50–74. After weighing the
balance of harms and benefits for women aged 40–49, screening
was not recommended routinely for women in their forties.
Instead, the USPSTF suggested an individualized approach taking
patient risk and personal preference into account. In contrast,
2017 guidelines from the American College of Radiology and the
Society of Breast Imaging currently recommend annual screening
starting at age 40.12 The American Cancer Society has revised their
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guidelines and recommend annual mammograms for women
over 45 of average risk, with women between the ages of 40–44
provided the opportunity to begin annual screening. Women over
the age of 55 are recommended to receive biennial screening,
although annual screening may be considered.13
Although the academic debate has progressed little in these 30
years, what has changed is public awareness of this issue. The vast
press coverage of the Canadian National Breast Cancer Screening
Study (CNBCSS) in 2014 brought the potential harms of screening
into the public spotlight. Not only did the 25-year analysis of the
CNBCSS show, as it had at both 10 and 15 years, that annual
screening failed to reduce breast cancer mortality, it provided the
first-ever estimates of overdiagnosis in a population-based annual
screening program: half of all screen-detected non-palpable
cancers were estimated to be indolent lesions that would
otherwise never have come to clinical attention.14
For some, this result simply confirmed previous findings
showing that up to 20% of all cancers (50% of screen-detected
cancers) fall into the category of overdiagnosis15–17—meaning a
woman has a greater chance of being over-diagnosed than of
having her life saved by screening.18 Others pointed to studies
demonstrating there is little, if any overdiagnosis in breast
cancer,19, 20 labeling CNBCSS as a flawed analysis or simply the
latest way to attack screening. The debate reached such an
unhealthy tenor that published exchanges even included accusa-
tions of a scientific conspiracy to reduce access to mammogra-
phy.21, 22
Like the screening debates that preceded it, the controversy
surrounding overdiagnosis has now settled into a familiar pattern.
It focuses on largely technical arguments over statistical assump-
tions, corrections for lead time bias and varied demographics23, 24
that create uncertainties in the data and ultimately have shifted
the debate into the realm of opinion, rather than fact. Recent
characterization of a molecular profile to define an ultralow risk
biology may provide a tool to more objectively categorize ultralow
risk breast cancers that have little systemic risk of progression. This
is an important advance that may help us to improve our ability to
treat the disease and further tailor individual screening
recommendations.25
We must remember, however, that the data we are arguing over
are from decades-old trials, from an era before most of the
effective systemic therapies were available. That there is an impact
of modern systemic therapies on reducing breast cancer mortality
is undeniable—some estimate that systemic therapy accounts for
2/3 of the observed reduction in mortality.26, 27 The rise of
endocrine therapy28, 29 may also mitigate the impact of finding
some cancers later.
Whether one believes these figures or not, the takeaway is that
we are stuck in an endless cycle of academic debate, arguing over
data that have little context in the modern treatment setting.
Breast cancer treatment continues to rapidly evolve towards a
patient-centered, precision medicine approach that recognizes
what is perhaps the most important lesson we have learned over
the past two decades of research: that breast cancer is not a
monolithic entity, but a spectrum of disease. From indolent lesions
of epithelial origin (IDLE)9 requiring no treatment, to aggressive
disease requiring equally aggressive treatment, it has resisted all
our attempts to lump it into a single bin.
Yet we continue our one-size-fits-all approach to breast cancer
screening. It is contrary to the very nature of the disease. We
cannot continue to focus the entirety of our efforts on a screening
approach that is based on an outdated understanding of breast
cancer biology, expecting that the uncertainties and debate will
finally be resolved. Instead, we must be willing to innovate and to
entertain new paradigms of screening that incorporate our current
understanding of breast cancer, its treatment and risk suscept-
ibility by putting them to the test.
We may have little choice. Because the consequences of failing
to do so may be to further alienate the very women screening is
supposed to help.
WHAT WOMEN WANT: BETTER, NOT MORE SCREENING
Even though generations of women educated in the benefits of
screening mammography generally regard it positively, experi-
ence shows it is a fragile trust. A single false positive can cause
psychological distress for up to 3 years and reduce adherence to
subsequent screening by 37%.30–34
Considering the specificity of mammography is generally
accepted to be ~ 90% (e.g., 1 in 10 are false positive), whereas
the real breast cancer rate is ~ 5 in 1000 women, the majority of
abnormal mammograms are, in fact, false positives. After 10 years
of annual screening, over half of all women receive a false-positive
recall and 7–9% have a false-positive biopsy.35
Furthermore, in the wake of the CNBCSS, information concern-
ing overdiagnosis is increasingly available to women,36 under-
mining their confidence in screening. Women given controlled,
qualitative, and quantitative education on the risks of over-
diagnosis have less positive attitudes about screening and
demonstrate reduced intent to screen.37 Similarly, primary care
physicians, key influencers in a woman’s screening decisions, are
far less willing to refer patients 40–49 for screening when fully
educated about the potential risks/benefits of screening.38
Further, our conflicting recommendations have made this
divisive debate a public one, sowing distrust and a deepening
confusion for women over how to prevent the disease that scares
them the most.39, 40
The question we need to be asking, therefore, is not whether
we should screen more or less, earlier or later. It is how can we
make screening better for women, reduce false-positive recalls
and improve our ability to more accurately prevent and detect
clinically significant cancers sufficiently early. This is, after all, is
what women tell us they want41 and what we have observed to
date in the WISDOM trial (described below).
The answer is simply that we must move on. We must begin
developing and testing new and better approaches that respond
to women’s needs. Fortunately, in this respect, there is one thing
upon which we all agree—women must have the opportunity to
make informed screening choices.
INDIVIDUALIZED, INFORMED CHOICE
Overwhelmingly, women want information about their personal
risk of breast cancer.42, 43 Currently, only 10% have accurate
perceptions of their personal risk and 40% have never discussed
their personal breast cancer risk with a doctor.44 Yet, a realistic
view of their risk is prerequisite to making informed screening
decisions.
We have the tools to better inform women of their personal risk,
through well characterized models that incorporate family history
and breast density, endocrine exposures, gene mutations, and
atypia,45–49 along with a number of common gene variants.50, 51
They teach us that not all women whom we classify for screening
purposes as “average-risk,” actually have the same lifetime risk of
breast cancer. Armed with a better understanding of their
individual risk, such women will expect—and demand—screening
recommendations commensurate with their personal risk.
Unless we are prepared to ignore the modern tools available to
us, we are therefore compelled to shepherd breast cancer
screening into the era of precision medicine. Now is the time to
begin evaluating a patient-centric model, focusing on individually
tailored recommendations on when to start, when to stop, and
how often to screen, depending upon a woman’s personal risk.
Only through clinical testing can we establish the evidence that
tells us how best to apply risk.
The WISDOM Study
LJ Esserman et al.
2
npj Breast Cancer (2017)  34 Published in partnership with the Breast Cancer Research Foundation
The idea of risk-based screening is not revolutionary. In fact, we
already do it, although in a crude fashion. It is standard of practice
for high risk women with mutations in the BRCA genes and first
degree relatives from high risk families to begin screening at a
much earlier age, and to do so more frequently (annual
mammogram alternating with annual MRI).52 But our under-
standing of breast cancer risk goes much further than our current
screening recommendations reflect. Our failure to incorporate our
current understanding of personal risk into our screening
recommendations means we may be asking some women to
accept risk/benefit ratios they might not be comfortable with if
they were fully informed.
Within the context of well-designed, randomized, controlled
clinical trials, we have the ability to investigate new screening
models in a safe, systematic manner, beginning with conservative
estimates that minimize the chances of misclassification of risk
and avoid underscreening. If we are successful, it could help
establish a new baseline for cancer screening, reduce confusion
and anxiety for women over conflicting recommendations,
improve women’s perception of their true risk of breast cancer,
improve adherence,53 and reinforce confidence in providers.
Perhaps most importantly, it allows us to learn who is at risk for
what kind of cancer, and establish a cycle of continuous
improvement in breast cancer screening.
Risk-based screening may or may not be the answer to all of
screening’s shortcomings, but it is perhaps an answer to the
current deadlock in which we find ourselves. In the words of
philosopher David Hume, it is time “we start spilling our sweat,
and not our blood.”
THE WISDOM STUDY: OVERCOMING CHALLENGES
We have recently been awarded a grant from the Patient Centered
Outcomes Research Institute (PCORI) to evaluate a risk-based
screening approach within a pragmatic, controlled trial. The
“WIDSOM” study (Women Informed to Screen Depending On
Measures of risk) is a multicenter trial comparing risk-based
screening to annual screening in 100,000 women aged 40–74,
initially opening in the Athena Breast Health Network in California
and the Midwest (Table 1). The study is a “preference tolerant
design” (Fig. 1) that encourages women to be randomized (n~
65,000) but also allows self-assignment for those with strong
personal preference for either annual or risk-based screening (a
pilot study was conducted in 2015 in which 74% of women agreed
to randomization). Importantly, WISDOM is an adaptive design,
allowing us to learn and adjust, continuing to improve the risk-
assessment and screening recommendation models over the
course of the trial.
An essential aspect of developing WISDOM has been the
engagement of all stakeholders, including consumers, policy
makers/guideline organizations and multiple specialties, and
payers, to agree upfront on metrics for success. This ensures the
trial remains relevant to the needs of the end-user and sets the
stage for rapid adoption should it prove successful.
Patients and advocates in particular, through the Athena
Consumer and Community Advisory Committee, have been key
partners in WISDOM since its conception. The preference-tolerant
design that allows all women to participate regardless if they have
strong personal reservations about being randomized grew from
vigorous discussions with this group. The consumer voice is
deeply embedded in WISDOM, with influence in all aspects of
study design and planning, including enrollment strategies,
consent processes, primary care physician outreach and educa-
tion, risk notification, and participant retention.
The buy-in of health care payers is essential to enable rapid
dissemination once results are presented. Modeling shows a risk-
based strategy will be more cost effective in terms of screening,
but requires an initial outlay of resources for one-time genetic
testing and comprehensive risk assessments. After almost 2 years
of discussion and negotiation, WISDOM’s “Payer Working Group”,
led by Blue Shield of California and including all insurers in
California, has reached an agreement to implement a “Coverage
with Evidence Development” model to cover clinical costs not
funded through PCORI.54 This model allows innovative treatment
approaches to be tested transparently. The use of a coverage
model that fosters the development of evidence, using a coverage
with trial participation approach, allows agreement on metrics for
adoption and should shorten the timeline for adoption. By
engaging payers early, should the study prove successful, we will
have laid the foundations to address future challenges in
implementation related to standard coverage. We are in the
process of engaging other payers.
The most formidable challenge in terms of stakeholders in
developing a trial of risk-based screening, given the voracity of the
academic debate, lies within the academic community. Among
the highest priorities has been to define acceptable parameters of
risk assessment, stratification and screening recommendations.
We have also invested considerable effort to reach consensus
regarding what constitutes success. WISDOM’s ‘Risk Thresholds
Group’ and ‘Primary Care Physician Working Group,” consisting of
primary care teams, representatives of the radiology community
and others have shared these tasks.
RISK ASSESSMENTS AND RECOMMENDATIONS
The Breast Cancer Surveillance Consortium (BCSC) model was
selected as the foundation of individual risk assessments for
WISDOM, based on its accuracy, ease of implementation, its large
(>1 million women) multiethnic target population, and incorpora-
tion of ethnicity and breast density as risk factors.55, 56 Additional
assessments also include polygenic risk based on nearly 200 SNPs,
as well as a 9 high-penetrance gene mutation panel.
In translating individual risk to screening recommendations, the
primary consideration of the working groups was to develop
guidelines that were sufficiently conservative to minimize risk of
potential harm from underscreening, yet progressive enough to
minimize potential harm from overdiagnosis, while permitting
outcome measures with sufficient study power. The consensus risk
stratification and related screening recommendations to be
employed within WISDOM are shown in Table 2, and include
more frequent screening for those at highest risk or those at risk
for faster growing (e.g., hormone negative) cancer. In the risk-
based assessment arm, no woman will receive a recommendation
for less screening than current USPSTF guidelines—individual
risk≥ 1.3% over 5 years initiates screening. Because the uptake of
risk-reducing interventions has been very poor despite level 1
evidence of benefit, we will use a stringent threshold (top 2.5
percentile of risk for breast cancer by age group, or lifetime risk in
the range of 30% or higher) for identifying participants to target
and counsel about endocrine risk-reducing therapy. The gene-
based tests also inform the risk for hormone positive or negative
breast cancer and impact screening and prevention recommenda-
tions. Additional details on the rationale and evidence used to
develop this model are published elsewhere.57, 58
A shared decision-making (e-prognosis) tool based on recent
modeling of comorbidity and impact of screening59 will be used
to identify women unlikely to benefit from screening due to
limited life expectancy. These rules will inform our risk assign-
ments, age to start, age to stop, frequency, and appropriate
modality of screening. The trial is designed to adapt over time,
and refine categorization and screening frequency based on the
actual cancer rate and biology of tumors that develop.
The WISDOM Study
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Table 1. The WISDOM Study At-a-glance
Rationale • In >30 years of screening, little change in approach
• No clear evidence that annual mammograms reduce breast cancer mortality rates compared to biennial
mammograms
• Morbidity associated with annual screening—false positives, over-diagnosis/overtreatment of indolent disease—
could safely be reduced
• Conflicting screening recommendations for women in their 40’s has resulted in confusion for patients, who want
more personalized advice
Hypotheses Personalized breast cancer screening recommendations based on individual risk assessments will: (1) be at least as
safe and less morbid than annual screening; (2) result in improved breast cancer prevention; and (3) be readily
accepted by women and preferred over standard annual screening.
Primary endpoint(s) (i) Safety: comparative rate of stage IIB cancers or higher diagnosed in annual vs. risk-based screening arms (non-
inferiority); and
(ii) Morbidity: reduced rate of recall and breast biopsy between arms
Secondary endpoint(s) • Rate of stage IIB and interval cancers
• Recall rates and follow-up procedures
• Rates of DCIS
• Rates of chemoprevention use and cancer incidence
• Proportion of women enrolling in randomized cohort vs. self-assigned cohort
• Within the self-assigned cohort, proportion of women choosing risk-based screening vs. standard annual screening
to assess preference
• Adherence to assigned screening schedule
• PROMIS anxiety score
• Breast cancer risk worry
• Decision regret
• Rates of systemic therapy (comparative differences in treatment stratified by tumor type)
• Distribution of biological tumor subtypes, including ultralow risk and DCIS
Integral biomarkers: Components of individual risk assessmenta:
(i) Breast Cancer Surveillance Consortium (BCSC) 5-year risk which includes:
• Age
• Race/ethnicity
• First degree relatives with breast cancer
• Prior breast biopsies (+ve or –ve)
• Proliferative breast condition (atypia)
• BI-RADS breast density score
(ii) Genomic tests for rare high/moderate-penetrance mutations in a number of genes, including the following: BRCA1,
BRCA2, ATM, CDH1, CHEK2, PALB2, PTEN, STK11 and TP53
(iii) Polygenic risk score from 96 lower-risk common genetic variants (SNPs) with known association to breast cancer
(updated as data as data emerges)
(iv) 10 year life expectancy as assessed by e-prognosis
(v) Special risk factors such as history of chest irradiation
Integrated biomarkersa: (i) Updated polygenic risk model (including ethnicity and race specific SNPs that are shown to confer risk (258 under
assessment)
(ii) Risk factors associated with subtype specific breast cancer, including ultralow risk or indolent lesions, molecular
subtypes, interval cancers
Sample size (and power) Sample size:
Total of 100,000 participants (~ 65,000 in randomized cohort, ~ 35,000 in self-assigned cohort)
Statistical power:
• 90% to detect a <0.05% difference in risk of diagnosis with Stage IIB or higher in the personalized vs. annual arm in a
given year
• 90% power to detect a difference in number of recall biopsies as small as 1.1% between personalized vs. annual arm
Patient population (3 bullets) • Women, aged 40–74 years at enrollment
• No prior history of cancer or DCIS
• Willing to sign informed consent and provide follow-up data
a As risk models improve over time, the optimal risk model will be updated and used for risk assignments, as we are testing the concept of risk-based
screening, not simply a specific risk model
The WISDOM Study
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DEFINING SUCCESS
If, after completing WISDOM, we are to avoid simply adding
additional fuel to the fire of the screening debate, the scientific
questions we ask must be well defined and the answers definitive.
This is particularly challenging given the nature of the current
debate and is further complicated by statistical requirements,
population size limitations and the 5-year follow-up limitation of
the funding. Such deliberations within WISDOM working groups
strengthened the study significantly, emphasized safety as the
overriding priority and established a series of outcomes with
achievable and highly relevant goals.
WISDOM’s primary endpoints are, first, to determine whether
risk-based screening is non-inferior to annual screening for late-
stage cancers detected. The outcome is the number of Stage IIB or
higher cancers found using personalized vs. annual screening. The
study has been powered assuming annual incidence rates of 95
Stage IIB or higher cancers per 100,000 women in each arm.60
Over 65,000 randomized patients, this provides 90% power to
detect a difference lower than 0.05% in risk of being diagnosed
with Stage IIB or higher in the personalized vs. annual arm in a
given year (83% for a difference <0.035%).58
Second, we will compare the morbidity of personalized vs.
annual screening on the basis of the number of biopsies
performed. Assuming 16% of first time mammograms and 8% of
subsequent screens lead to false positive recalls,61 65,000 patients
equally randomized between annual and personalized screening
offers 90% power to detect a difference as small as 1.1% (22 vs.
20.9%).
Additional secondary objectives will further our understanding
of the impacts of personalized screening and include measures of
morbidity (e.g., rates of systemic therapy, rates of DCIS,
chemoprevention) and the comparative attitudes and acceptance
of each screening modality by women enrolled in the trial (e.g.,
adherence, measures of anxiety, decision regret). Finally, we will
determine whether an understanding of personalized risk,
especially the ability to predict hormone positive breast cancer,
will provide better motivation for and uptake of endocrine risk
reducing therapies and lifestyle changes.
Since opening in September 2016, Over 4000 women have
enrolled in WISDOM. About two-thirds have agreed to randomiza-
tion. The other one-third opted to self-select their screening
approach in the observation arm: 85% have elected for
personalized screening. Although preliminary, our experience to
date provides critical insight into the comfort women feel with the
concept of individualized, risk-based screening.
CONCLUSIONS
The United States is the only country where annual screening
starting at age 40 is standard practice, yet our breast cancer
mortality rate is no better than countries that screen less.62 Clearly,
there is room for improvement. Progress will only come by
investigating other possibilities. The WISDOM study will evaluate
one such possibility—screening based on a woman’s individual
risk—opening its first site in August 2016, expanding to other sites
nationally in 2017. It is certainly unlikely that all women benefit
equally from screening. Investing in pragmatic studies like
WISDOM allows us to learn who is at risk for what kind of breast
cancer, tailor screening accordingly and build a new framework
for continuous improvement.
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